Literature DB >> 28736235

HLA-A*26 Is Correlated With Response to Nivolumab in Japanese Melanoma Patients.

Yoshihiro Ishida1, Atsushi Otsuka2, Hidenori Tanaka3, Mitchell P Levesque4, Reinhard Dummer4, Kenji Kabashima5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28736235     DOI： 10.1016/j.jid.2017.06.023

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  7 in total

Review 1.  Immune Dysregulation in Cancer Patients Undergoing Immune Checkpoint Inhibitor Treatment and Potential Predictive Strategies for Future Clinical Practice.

Authors:  Ronald Anderson; Bernardo L Rapoport
Journal:  Front Oncol       Date:  2018-03-22       Impact factor: 6.244

Review 2.  Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events.

Authors:  Yoshiyuki Nakamura
Journal:  Front Med (Lausanne)       Date:  2019-05-29

Review 3.  Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations.

Authors:  Judith A Seidel; Atsushi Otsuka; Kenji Kabashima
Journal:  Front Oncol       Date:  2018-03-28       Impact factor: 6.244

4.  Killer immunoglobulin-like receptor genotype did not correlate with response to anti-PD-1 antibody treatment in a Japanese cohort.

Authors:  Yoshihiro Ishida; Chisa Nakashima; Hiroto Kojima; Hidenori Tanaka; Taku Fujimura; Shigeto Matsushita; Yuki Yamamoto; Koji Yoshino; Yasuhiro Fujisawa; Atsushi Otsuka; Kenji Kabashima
Journal:  Sci Rep       Date:  2018-10-29       Impact factor: 4.379

Review 5.  Biomarkers for Immune Checkpoint Inhibitors in Melanoma.

Authors:  Shigehisa Kitano; Takayuki Nakayama; Makiko Yamashita
Journal:  Front Oncol       Date:  2018-07-18       Impact factor: 6.244

6.  Variable indoleamine 2,3-dioxygenase expression in acral/mucosal melanoma and its possible link to immunotherapy.

Authors:  Natsuko Iga; Atsushi Otsuka; Masahiro Hirata; Tatsuki R Kataoka; Hiroyuki Irie; Chisa Nakashima; Shigeto Matsushita; Hiroshi Uchi; Yuki Yamamoto; Takeru Funakoshi; Yasuhiro Fujisawa; Koji Yoshino; Taku Fujimura; Hiroo Hata; Yoshihiro Ishida; Kenji Kabashima
Journal:  Cancer Sci       Date:  2019-09-30       Impact factor: 6.716

7.  Biomarkers Associated with Immune-Related Adverse Events under Checkpoint Inhibitors in Metastatic Melanoma.

Authors:  Marcus Wölffer; Florian Battke; Martin Schulze; Magdalena Feldhahn; Lukas Flatz; Peter Martus; Andrea Forschner
Journal:  Cancers (Basel)       Date:  2022-01-08       Impact factor: 6.639
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.